← Eichor
Study identifier: NCT06693973 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Condition: B-cell Non-Hodgkin Lymphoma (B-NHL)  ·  Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

PhaseEARLY_Phase 1
Planned participants13
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to determine whether AcNK-Sup003 cell injection is safe and effective in the treatment of elapsed or refractory B-cell non-Hodgkin's lymphoma.

This description comes directly from the study's public registry record.

Talk to the study team

Heng Mei, Ph.D&M.D  ·  027-8572600  ·  hmei@hust.edu.cn

Jia Xu  ·  18274201261  ·  xu_jia@hust.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06693973